Expression of TRAP1 predicts poor survival of malignant glioma patients.
TRAP1/Hsp75 (tumor necrosis factor receptor-associated protein 1), a paralogue of the Hsp90 family, has been recently described as a molecular marker and novel therapeutic target in local and metastatic prostate cancer. It has been proved to be associated with tumor invasion and metastasis in various human malignancies. In our study, the protein expression level of TRAP1 in 236 cases of glioma is investigated by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of TRAP1 with clinicopathological characteristics and prognosis of patients. It was proved that TRAP1 protein expression was increased in glioma compared with that in normal brain tissue. Moreover, TRAP1 immunohistochemical staining was correlated with World Health Organization (WHO) grade and Karnofsky performance score (KPS). Strong positive TRAP1 staining is more frequently detected in glioma of advanced grade or low KPS. It is also demonstrated that TRAP1 could be an independent negative prognostic factor in glioma, for patients with glioma of strong TRAP1 staining tend to have high risk of death. These results proved that TRAP1 is associated with prognosis of glioma, which may also suggest the potential role of TRAP1 in glioma management.